Chandasana, Hardik, Ann M Buchanan, Cassidy A Henegar, Michael McKenna, Cindy Vavro, Ana Puga, Cindy Brothers, et al. 2026. “Model-Informed Dolutegravir Dose Selection in Pediatrics With First-Generation INSTI Resistance.”. The Pediatric Infectious Disease Journal.
Abstract
Twice-daily dosing of Dolutegravir is approved for adults with HIV and integrase strand transfer inhibitor resistance, but not for children. Population pharmacokinetic modeling and simulations identified a weight-tiered twice-daily dose for children, predicted to yield dolutegravir exposures within the therapeutic window and provide similar efficacy and safety as seen in adults with HIV-1 and first-generation integrase strand transfer inhibitor resistance.